Subscribe to RSS
DOI: 10.1055/a-1971-8781
The Clinical Characteristics and Outcomes of COVID-19 Patients with Pre-Existing Thyroid Dysfunction: A Nationwide Study
Abstract
To which extent the pre-existing hypothyroidism or hyperthyroidism has an impact on coronavirus infection 2019 (COVID-19) outcomes remains unclear. The objective of this study was to evaluate COVID-19 morbidity and mortality in patients with pre-existing thyroid dysfunction. A retrospective cohort of patients with a polymerase chain reaction (PCR)-confirmed COVID-19 infection (n=14 966) from March 11 to May 30, 2020, was established using the database of the Turkish Ministry of Health. We compared the morbidity and mortality rates of COVID-19 patients with pre-existing hypothyroidism (n=8813) and hyperthyroidism (n=1822) to those patients with normal thyroid function (n=4331). Univariate and multivariate regression analyses were performed to identify the factors associated with mortality. Mortality rates were higher in patients with hyperthyroidism (7.7%) and hypothyroidism (4.4%) than those with normal thyroid function (3.4%) (p<0.001 and p=0.008, respectively). Pre-existing hyperthyroidism was significantly associated with an increased risk of mortality (OR 1.54; 95% CI, 1.02–2.33; p=0.042) along with advanced age, male gender, lymphopenia and chronic kidney disease (p<0.001 for all). Although a potential trend was noted, the association between pre-existing hypothyroidism and mortality was not significant (OR 1.36; 95% CI, 0.99–1.86; p=0.055). In conclusion, this study showed an association between pre-existing hyperthyroidism with higher COVID-19 mortality. A potential trend towards increased mortality was also observed for hypothyroidism. The risk was more pronounced in patients with hyperthyroidism.
Publication History
Received: 11 May 2022
Accepted after revision: 03 November 2022
Accepted Manuscript online:
03 November 2022
Article published online:
09 December 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Republic of Turkey Ministry of Health COVID-19 Information Page. Available at https://covid19.saglik.gov.tr/; Accessed on Feb 02, 2022
- 2 Hu J, Li C, Wang S. et al. Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data. Hum Genomics 2021; 15 Article Number 10
- 3 Sonmez A, Demirci I, Haymana C. et al. Clinical characteristics and outcomes of COVID-19 in patients with type 2 diabetes in Turkey: a nationwide study (TurCoviDia). J Diabetes 2021; 13: 585-595
- 4 Hariyanto TI, Kurniawan A.. Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Sleep Med 2021; 82: 47-53
- 5 Sahin I, Haymana C, Demir T. et al. Clinical characteristics and outcomes of COVID-19 patients with overweight and obesity: Turkish nationwide cohort study (TurCObesity). Exp Clin Endocrinol Diabetes 2022; 130: 115-124
- 6 Sahin M, Haymana C, Demirci I. et al. The clinical outcomes of COVID-19 infection in patients with a history of thyroid cancer: a nationwide study. Clin Endocrinol (Oxf) 2021; 95: 628-637
- 7 Taylor PN, Albrecht D, Scholz A. et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol 201 14: 301-316
- 8 Journy NMY, Bernier MO, Doody MM. et al. Hyperthyroidism, hypothyroidism, and cause-specific mortality in a large cohort of women. Thyroid 2017; 27: 1001-1010
- 9 Akirov A, Gimbel H, Grossman A. et al. Elevated TSH in adults treated for hypothyroidism is associated with increased mortality. Eur J Endocrinol 2017; 176: 57-66
- 10 Thvilum M, Brandt F, Almind D. et al. Excess mortality in patients diagnosed with hypothyroidism: a nationwide cohort study of singletons and twins. J Clin Endocrinol Metab 2013; 98: 1069-1075
- 11 Sohn SY, Seo GH, Chung JH.. Risk of sll-cause mortality in levothyroxine-treated hypothyroid patients: a nationwide Korean cohort study. Front Endocrinol (Lausanne) 2021; 12: 680647
- 12 Brandt F, Green A, Hegedüs L. et al. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol 2011; 165: 491-497
- 13 Brandt F, Thvilum M, Almind D. et al. Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PloS One 2013; 8: e66711
- 14 Owen PJ, Sabit R, Lazarus JH.. Thyroid disease and vascular function. Thyroid 2007; 17: 519-524
- 15 Elbers LPB, Fliers E, Cannegieter SC.. The influence of thyroid function on the coagulation system and its clinical consequences. J Thromb Haemost 2018; 16: 634-645
- 16 Olivieri A, Sorcini M, Battisti P. et al. Thyroid hypofunction related with the progression of human immunodeficiency virus infection. J Endocrinol Invest 1993; 16: 407-413
- 17 van der Spek AH, Fliers E, Boelen A.. Thyroid hormone metabolism in innate immune cells. J Endocrinol 2017; 232: R67-R81
- 18 Rubingh J, van der Spek A, Fliers E. et al. The role of thyroid hormone in the innate and adaptive immune response during infection. Compr Physiol 2020; 10: 1277-1287
- 19 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-280.e8
- 20 Carneiro-Ramos MS, Silva VB, Santos RA. et al. Tissue-specific modulation of angiotensin-converting enzyme (ACE) in hyperthyroidism. Peptides 2006; 27: 2942-2949
- 21 Damara FA, Muchamad GR, Ikhsani R. et al. Thyroid disease and hypothyroidism are associated with poor COVID-19 outcomes: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 2021; 15: 102312
- 22 Pereira DN, Silveira LFG, Guimarães MMM. et al. Hypothyroidism does not lead to worse prognosis in COVID-19: findings from the Brazilian COVID-19 registry. Int J Infect Dis 2022; 116: 319-327
- 23 Levey AS, Stevens LA, Schmid CH. et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612 Erratum in: Ann Intern Med 2011; 20; 155: 408
- 24 Brix TH, Hegedüs L, Hallas J. et al. Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism. Lancet Diabetes Endocrinol 2021; 9: 197-199
- 25 van Gerwen M, Alsen M, Little C. et al. Outcomes of patients with hypothyroidism and COVID-19: a retrospective cohort study. Front Endocrinol (Lausanne) 2020; 11: 565
- 26 Okosieme OE, Taylor PN, Evans C. et al. Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol 2019; 7: 278-287
- 27 Lillevang-Johansen M, Abrahamsen B, Jørgensen HL. et al. Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH. J Clin Endocrinol Metab 2017; 102: 2301-2309
- 28 Lania A, Sandri MT, Cellini M. et al. Thyrotoxicosis in patients with COVID-19: the THYRCOV study. Eur J Endocrinol 2020; 183: 381-387